KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deffered Revenue: 2018-2020

Historic Non-Current Deffered Revenue for Castle Biosciences (CSTL) over the last 3 years, with Dec 2020 value amounting to $1.7 million.

  • Castle Biosciences' Non-Current Deffered Revenue fell 13.51% to $986,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $986,000, marking a year-over-year decrease of 13.51%. This contributed to the annual value of $1.7 million for FY2020, which is 3054.55% up from last year.
  • According to the latest figures from FY2020, Castle Biosciences' Non-Current Deffered Revenue is $1.7 million, which was up 3,054.55% from $55,000 recorded in FY2019.
  • Castle Biosciences' Non-Current Deffered Revenue's 5-year high stood at $1.7 million during FY2020, with a 5-year trough of $44,000 in FY2018.
  • In the last 3 years, Castle Biosciences' Non-Current Deffered Revenue had a median value of $55,000 in 2019 and averaged $611,333.
  • Data for Castle Biosciences' Non-Current Deffered Revenue shows a peak YoY spiked of 3,054.55% (in 2020) over the last 5 years.
  • Yearly analysis of 3 years shows Castle Biosciences' Non-Current Deffered Revenue stood at $44,000 in 2018, then rose by 25.00% to $55,000 in 2019, then skyrocketed by 3,054.55% to $1.7 million in 2020.